Trials / Withdrawn
WithdrawnNCT01666704
Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis
A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Effects of BMS-823778 on Atherosclerotic Plaque Inflammation as Measured by Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET) in Patients With Atherosclerotic Cardiovascular Disease
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the effect of BMS-823778 on reducing atherosclerotic plaque inflammation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-823778 | Capsules, Oral, 2mg, Once daily, 1 year |
| DRUG | BMS-823778 | Capsules, Oral, 15mg, Once daily, 1 year |
| DRUG | Placebo matching with BMS-823778 | Capsules, Oral, 0mg, Once daily, 1 year |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2015-10-01
- Completion
- 2016-05-01
- First posted
- 2012-08-16
- Last updated
- 2013-06-21
Source: ClinicalTrials.gov record NCT01666704. Inclusion in this directory is not an endorsement.